Reported 8 months ago
Shares of Gilead Sciences (GILD) surged 8% after the biopharma company announced 100% efficacy for its experimental twice-yearly HIV prevention medicine in a Phase 3 trial, a first in such trials showing zero infections. Analysts suggest this new drug could bring in over $1.7 billion in annual sales, potentially revitalizing Gilead's stock performance which is currently down 16% year-to-date.
Source: YAHOO